What is Sionna Therapeutics, Inc.'s market cap?

Sionna Therapeutics, Inc. (SION) has a market capitalization of $2.1B and trades on NASDAQ.

Who are Sionna Therapeutics, Inc.'s competitors?

Sionna Therapeutics, Inc.'s key competitors include Vertex Pharmaceuticals, AbbVie, Soligenix, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Where is Sionna Therapeutics, Inc. headquartered?

Sionna Therapeutics, Inc. is headquartered in United States of America. It has been publicly traded since 2025.

Sionna Therapeutics, Inc.

SION

Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule medicines to treat cystic fibrosis by normalizing the function of the CFTR protein.

Market cap

$2.05B+162%

Net income-$85.6M-29.0%

Free cash flow-$72.1M-28.8%

EPS (diluted)-$411.51+84.9%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 12, 2026

EPS-$0.60Miss by $0.08

Read the full report

Next report

Aug 10, 2026 (In 1 week)

EPS estimate-$0.64

Financials

Q1 2026

Income statement

See full

Operating income-$29.6M-50.6%

Net income-$26.8M-62.5%

EPS (diluted)-$0.60+3.2%

Balance sheet

See full

Cash & equivalents$64.3M-23.2%

Total debt$8.4M-11.8%

Total equity$288.2M-18.1%

Total assets$305.0M-17.5%

Cash flow

See full

Operating cash flow-$21.8M-34.1%

CapEx--100%

Free cash flow-$21.8M-33.4%

Valuation & ratios

Valuation

See full

Market cap$2.05B+162%

Enterprise value$1.99B+137%

Returns & leverage

See full

Return on equity-26.7%—

Debt / equity0×0.0×

Current ratio22.6×-6.1×

Competitors

By market cap

AbbVie$453.91B+36.3%

Vertex Pharmaceuticals$121.57B+2.7%

Sionna Therapeutics, Inc.$2.0B+134%

C4 Therapeutics$396.9M+156%

vTv Therapeutics$122.2M+200%

Clene Inc.$69.8M+128%

Cyclerion Therapeutics$15.2M+53.1%

Soligenix, Inc.$5.4M+28.4%

By revenue growth

Vertex Pharmaceuticals+10.1%

AbbVie+9.5%

By net margin

Vertex Pharmaceuticals35.51%+42.7pp

AbbVie5.79%-1.5pp

Profile

Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule medicines to treat cystic fibrosis by normalizing the function of the CFTR protein. The company specifically targets the nucleotide binding domain 1 (NBD1) to correct defects caused by the F508del mutation, which affects approximately 90% of cystic fibrosis patients. Their core value proposition lies in achieving near-normal CFTR function through novel NBD1 stabilizers that can be used as monotherapies or in combination with other modulators.

Competitive position

A clinical-stage innovator targeting the previously 'undruggable' NBD1 domain to differentiate from existing CFTR modulators.

GeographiesGlobal

Customer segmentsPatients, Healthcare Providers

Business modelBiopharmaceutical R&D

SuppliersContract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs), Raw Material Suppliers

CustomersSpecialty Distributors, Hospitals, Patients with F508del mutation

CountryUnited States of America

Listed2025

CEOMichael Cloonan

SectorHealthcare

IndustryBiotechnology

Websitesionnatx.com

FilingsSEC EDGAR

Questions, answered.

What is Sionna Therapeutics, Inc.'s market cap?: Sionna Therapeutics, Inc. (SION) has a market capitalization of $2.1B and trades on NASDAQ.
Who are Sionna Therapeutics, Inc.'s competitors?: Sionna Therapeutics, Inc.'s key competitors include Vertex Pharmaceuticals, AbbVie, Soligenix, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Where is Sionna Therapeutics, Inc. headquartered?: Sionna Therapeutics, Inc. is headquartered in United States of America. It has been publicly traded since 2025.